Skip to main content

Table 1 Patient Demographics and Prior Treatment Received

From: Successful mobilization using a combination of plerixafor and G-CSF in pediatric patients who failed previous chemomobilization with G-CSF alone and possible complications of the treatment

Pt # Dx Sex Age Earlier chemotherapy Earlier
radiotherapy
1st line mobilization
chemotherapy
1 NBL M 11 CDDP + VP16 + ADR + CPM, CPM + Topo + VP16 No CPM + VP16+ GCSF
2 MBL F 11 CDDP + CPM + VCR, CPM + VCR, Carbo + VP16 + IFM + VCR IFRT + CSI Carbo + VP16 + IFM + VCR + GCSF
3 OSA M 6 CDDP + ADR + MTX, IFM + ADR + MTX No CPM + VP16+ GCSF
4 OSA F 10 CDDP + ADR + MTX, IFM + ADR + MTX, Gemcitabine + Doxetaxel, CPM + Topo + VP16, IFM + Carbo + VP16 No CPM + VP16+ GCSF
5 MBL M 10 CDDP + CPM + VCR, CPM + VCR IFRT + CSI Carbo + VP16 + IFM + VCR + GCSF
6 ES F 15 VCR + ADR + CPM, IFM + VP16 No CPM + VP16+ GCSF
  1. ADR Doxorubicin, Carbo Carboplatin, CDDP Cisplatin, CPM cyclophosphamide, CSI Craniospinal axis irradiation, ES Ewing sarcoma, G-CSF Granulocyte colony stimulating factor, IFM Ifosphamide, IFRT Involved field radiation therapy, LP Leukapheresis, MBL Medulloblastoma, MTX Methotrexate, NBL Neuroblastoma, OSA Osteosarcoma, Pt Patient, Topo Topotecan, VCR Vincristine, VP16 Etoposide